$PVSP (“Pervasip” or the “Company”), a developer
$PVSP (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its 3rd Quarter ended August 31, 2022.
“Q3 2022 shows material signs of improvement over Q2 2022 reflecting our ongoing operational focus. As stated before, we continue to pursue our strategic goals even during these difficult market conditions as evidenced by our recent agreements on terms for the acquisition of the Emerald City Cultivation and Dabco brands. Our operational and financial focus on rationalizing our business, shedding underperforming assets, and increasing production yields by our independent cultivators continues to proceed and have allowed us to continue with additional market share capture. Investing in Cannabis is not for the faint of heart and we believe we are building a solid foundation for years to come which takes time, patience, and relentless focus on fundamentals. In an industry that does not have access to traditional financing, our options are limited and expensive,” said German Burtscher, Pervasip’s CEO. “We slowed the rollout of our new concentrate brands which we licensed for Q3 deployment and instead focused on an outright acquisition as the opportunity became available. That resulted in not meeting the forecasted revenue from the new product lineup for Q3. We are also pursuing a conservative approach to working within the complicated tax environment our industry is confronted with. Ongoing work in support of the audit process and a recent court ruling that impacts the cannabis industry caused us to change our estimates for tax liability dating back to prior periods 2017 – 2020, which we booked in Q3.”
The Company continues to focus on moving available bulk inventory into higher margin brands with a focus on margin capture and is seeing promising early results.
Third Quarter 2022 Financial Results
Q3 2022 versus Q2 2022
Q3 2022 operating results improved over Q2 2022, tracking with ongoing efforts to shift bulk sales to higher margin brands combined with relative COGs reductions, even when adjusted for inventory.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....
Continue Reading
Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...
Continue Reading
Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...
Continue Reading
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue Reading
A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...
Continue Reading
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
Continue Reading
Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...
Continue Reading
Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...
Continue Reading
Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...
Continue Reading
Top 5 Most Recently Viewed Articles
WTW Appoints New Leader for Business Development In a significant move to enhance its operations, WTW (NASDAQ: WTW) has announced the appointment of Dale Porfilio as Senior Director and Head of Personal and Commercial Lines Business Development within its Insurance Consulting & Technology (ICT) segment. A Seasoned Professional Joins WTW Porfilio brings a wealth of...
Continue Reading
Jorgen Vig Knudstorp Invests in Starbucks, Showing Strong Confidence Recently, Jorgen Vig Knudstorp, a director at Starbucks Corp (NASDAQ:SBUX), made a significant move by buying shares of the company. This act signals a firm vote of confidence in the future of the beloved coffee chain. When insiders make such investments, it often grabs the attention of other investors...
Continue Reading
Inventiva Files its 2024 Half-Year Report Inventiva, a prominent clinical-stage biopharmaceutical company, is making significant strides in the healthcare sector. Focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis, commonly known as MASH/NASH, the company recently announced its filing of the 2024 Half-Year Report for the period...
Continue Reading
Anticipation Surrounding Organon's Earnings Report Organon (OGN) is on the verge of revealing its quarterly earnings report, a moment eagerly awaited by investors. As preparations finalize for this significant announcement, understanding the forecasted outcomes can guide investor decisions moving forward. Expected Earnings Figures Forecast estimates suggest that Organon...
Continue Reading
Understanding the Miami-Dade Real Estate Market Miami-Dade County's real estate landscape is shifting, with older condominiums experiencing quicker sales than their newer counterparts. This trend indicates a solid demand for older condos, highlighting their appeal in a market where affordable housing options continue to thrive. Statistical data reveal that older...
Continue Reading